Tumblelog by Soup.io
Newer posts are loading.
You are at the newest post.
Click here to check if anything new just came in.

Dr. Dale Schenk To Participate On Expert Panel At World Medical Innovation Forum: Neurosciences - Yahoo Finance

San Francisco Salt Company Teams Up With the National Psoriasis Foundation for... -- SAN FRANCISCO, April 22, 2015 /PRNewswire/ --

EDT. Dr. Schenk will participate on the panel entitled, "The Alzheimer's Phoenix: New Technologies, New Economics." Other members of the panel include Michael Hutton, PhD, Chief Scientific Officer of Neurodegenerative Diseases for Eli Lilly & Co; Brad Hyman, MD, PhD, Director of the Massachusetts General Hospital Alzheimer's Disease Research Center and John B. Penney Jr. Professor of Neurology, Harvard Medical School; Roger Nitsch, PhD, Director of the Division of Psychiatry Research at the University of Zurich; and, Dennis Selkoe, MD, Co-Director of the Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and the Vincent and Stella Coates Professor of Neurologic Diseases, Harvard Medical School. The panel will be moderated by Rudolph Tanzi, PhD, Director of Genetics and Aging Research Unit of the Massachusetts General Institute for Neurodegenerative Disease & Joseph P.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/dr-dale-schenk-participate-expert-200500628.html

Novartis (NVS) Beats on Earnings in Q1, View Reiterated - Analyst Blog - Yahoo Finance

Only about 2 percent of asthma patients on the lowest dose of steroids experienced adrenal insufficiency, compared with about 22 percent on the highest doses. Similarly, slightly more than 1 percent of asthma patients on short-term steroids developed adrenal insufficiency, compared with about 27 percent on long-term treatment. There is no way to safely halt treatment with corticosteroids that can rule out the potential for adrenal insufficiency, Dekkers said. The side effect is more likely when patients take higher doses of steroids or remain on treatment for longer than three weeks, said Dr. Roberto Salvatori, medical director of the pituitary center at Johns Hopkins Hospital in Baltimore. "It's likely, and it's often overlooked because most often the people who prescribe corticosteroids aren't endocrinologists; they are in other specialities and they don't recognize the symptoms of adrenal insufficiency," said Salvatori, who wasn't involved in the study He gives his patients on corticosteroids medical identification bracelets or necklaces to wear so they can be identified as at risk for adrenal insufficiency in an emergency.
For the original version including any supplementary images or video, visit http://news.yahoo.com/common-asthma-steroids-linked-side-effects-adrenal-glands-182107481.html

Common asthma steroids linked to side effects in adrenal glands | Fox News

People with adrenal insufficiency do not make enough of two hormones, cortisol and aldosterone. Cortisol helps the body respond to stress, recover from serious about psoriasis infections and regulate blood pressure and metabolism. Aldosterone helps maintain the right amounts of salt, potassium and water in the body. While on steroids, the body often produces less of these hormones naturally, and after coming off the drugs it can take a while for natural production to ramp back up. The result is adrenal insufficiency, which can be treated with medication to replace cortisol or aldosterone. Dekkers and colleagues analyzed 74 research articles published from 1975 to 2014, covering a total of 3753 study participants, to see how different doses and types of corticosteroid treatment might impact the likelihood of developing adrenal insufficiency after treatment. Researchers found the risk of adrenal insufficiency was highest when corticosteroids were taken orally or injected, and lower with inhaled, nasal or topical treatment.
For the original version including any supplementary images or video, visit http://www.foxnews.com/health/2015/04/24/common-asthma-steroids-linked-to-side-effects-in-adrenal-glands/

Common asthma steroids linked to side effects in adrenal glands - Yahoo News

The healing psoriasis naturally company raised its full-year earnings to $4.10 to $4.30, from $4.05 to $4.25. fell $1.35, or 2.1 percent, to $63.17 in morning trading. Following the break-up of its planned trans-Atlantic merger with Shire, AbbVie has pushed ahead with other efforts to diversify its offerings.
For the original version including any supplementary images or video, visit http://news.yahoo.com/abbvie-raises-outlook-humira-again-144544333.html

Celgene Earnings Preview: What You Need to Know (CELG,AGIO)

\" />

 and biosimilars led to strong growth on recent launches. Biosimilars generated sales of $122 million, up 19%. We remind investors that in Mar 2015, Novartis acquired certain oncology products and pipeline compounds from GlaxoSmithKline GSK for $16 billion. In exchange, it sold the non-influenza Vaccines business to Glaxo for $7.1 billion. Novartis also completed the divestment of its animal health division to Eli Lilly and Company LLY in Jan 2015. In Jan 2014, Novartis completed the sale of its blood transfusion diagnostics unit to Grifols S.A. for $1.7 billion. 2015 Outlook Reiterated Novartis expects sales to grow in mid-single digits in 2015. <br />For the original version including any supplementary images or video, visit <a href=colloidal silver psoriasis Dermatology at the University of California San Francisco (UCSF) Medical Center. SF Salt will participate in the event and provide information and samples to participants. SF Salt will also be present at the 2015 Commit to Cure Gala being held on July 25th at the Westin St. Francis in San Francisco. This event will draw in all the major supporters from around the United States to honor Dr. Koo, one of the leading researchers of Psoriasis. On October 3rd, SF Salt will sponsor the Youth Ambassador for the TeamNPF Walk San Francisco. This family friendly event will start at the Justin Herman Plaza where participants will select a 1K or 5K route along the Embarcadero. There will be also be a Health Fair, Kid Zone (also sponsored by SF Salt), music by local bands, and testimonies presented by people thriving with psoriatic disease.
For the original version including any supplementary images or video, visit http://www.prnewswire.com/news-releases/san-francisco-salt-company-teams-up-with-the-national-psoriasis-foundation-for-2015-events-300069916.html

As we approach Celgene's Q1 release, I'd suggest paying close attention to any commentary management makes regarding future collaborative efforts, and/or any new clinical data being unveiled. Collaborations may cost Celgene money up-front, but it's the perfect recipe for delivering organic growth. Any chance of a dividend? Lastly, I'm interested to see if management has changed its tune at all with respect to paying a dividend. Previously, Celgene's management team had suggested the prospect of a dividend was probably a ways off. This isn't too much of a surprise considering that Celgene shuffles a lot of its cash flow into its collaborations and existing clinical development. However, a few of Celgene's comparably sized peers have begun paying a dividend, leading some investors to wonder whether Celgene might also decide to begin paying some form of quarterly stipend to investors. Since 2009, Celgene's operating cash flow has more than tripled from $910 million to $2.8 billion in 2014, leaving plenty of extra cash on the table to potentially return something to investors.
For the original version including any supplementary images or video, visit http://www.investopedia.com/stock-analysis/042415/celgene-earnings-preview-what-you-need-know-celg-agio.aspx?partner=newscred

Don't be the product, buy the product!